75.28
  Price5.78%   -4.62
(After Hours: 76.45 +1.17 +1.55%)
Nov-29-21 06:00AM Will This Beaten-Down Stock Bounce Back? 3 Things to KnowThe Motley Fool
Nov-23-21 12:01PM CRISPR's (CRSP) CAR-T Cell Therapy Gets FDA's RMAT DesignationZacks Investment Research
08:30AM CRISPR Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswire Inc.
Nov-22-21 08:30AM CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX110™ for the Treatment of Relapsed or Refractory CD19+ B-cell malignanciesGlobeNewswire Inc.
Nov-21-21 11:31AM Do CRISPR Therapeutics and Intellia Face a Big Safety Risk?The Motley Fool
Nov-20-21 07:00AM Better Buy: Vertex Pharmaceuticals vs. CRISPRThe Motley Fool
Nov-17-21 11:15AM 2 Beaten-Down Growth Stocks You Can Buy Right NowThe Motley Fool
10:45AM CRISPR (CRSP) to Begin Clinical Study on Diabetes Therapy DrugZacks Investment Research
Nov-11-21 06:47AM The Key Behind Vertex's Great Q3 ResultsThe Motley Fool
Nov-09-21 09:15AM Cathie Wood's Buying Beam Therapeutics -- Should You?The Motley Fool
Nov-05-21 06:00AM Can Vertex Make Billions With a New Game-Changing Treatment? The Answer May Be Just AheadThe Motley Fool
Nov-04-21 09:43AM Why CRISPR Therapeutics Stock Fell 18.4% in OctoberThe Motley Fool
07:37AM CRISPR Therapeutics (CRSP) Q3 Earnings Beat, Revenues LagZacks Investment Research
Nov-04-21 06:31AM Why Vertex Is Striking Another Gene-Editing Deal With a Company Not Named CRISPR TherapeuticsThe Motley Fool
06:05AM 3 No-Brainer Biotech Stocks to Buy in NovemberThe Motley Fool
Nov-03-21 05:15AM CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research
10:48AM Vertex (VRTX) Beats on Q3 Earnings & Sales, Raises '21 ViewZacks Investment Research
Nov-03-21 05:51AM 5 Biotech Stocks With 105% to 386% Upside, According to Wall StreetThe Motley Fool
Nov-02-21 06:52AM Could This Drug Become Vertex Pharmaceuticals' Next Blockbuster?The Motley Fool
Oct-26-21 05:55AM 3 Stocks Cathie Wood Is Buying That You Might Want to Consider TooThe Motley Fool
Oct-17-21 09:01AM 2 Gene-Editing Stocks to Have on Your Radar Right NowThe Motley Fool
Sep-27-21 10:08AM 3 Biotech Stocks That Could Make You Filthy RichThe Motley Fool
Sep-25-21 06:20AM September Sell-Off Alert: Buy Vertex Pharmaceuticals on the DipThe Motley Fool
Sep-23-21 05:55AM Why Cathie Wood Is Buying 2 Gene-Editing Stocks but Selling AnotherThe Motley Fool
Sep-22-21 02:30AM 5 Stocks to Buy in the September Sell-OffThe Motley Fool
Sep-21-21 06:45AM Is Now the Time to Ditch Pharma Stocks?The Motley Fool
Sep-18-21 09:15AM A Second Week of Declines as September ContinuesZacks Investment Research
03:32AM Crispr: Bad News For Gene EditingSeeking Alpha
Sep-17-21 09:30AM Why CRISPR Therapeutics AG (CRSP) is a Top Stock for the Long-TermZacks Investment Research
Sep-16-21 05:55AM 3 Explosive Biotech Stocks That Could 10X in 10 YearsThe Motley Fool
Sep-15-21 11:36AM 5 Reasons to Buy Vertex Pharmaceuticals (VRTX) Stock NowZacks Investment Research
Sep-14-21 09:05AM 3 Crash-Ready Stocks to Buy in SeptemberThe Motley Fool
Sep-11-21 05:55AM 2 Biotech Stocks That Are Better Buys Than ModernaThe Motley Fool
Sep-09-21 12:37PM 3 Red-Hot Healthcare Stocks to Buy in SeptemberThe Motley Fool
07:52AM Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just BoughtThe Motley Fool
Sep-07-21 05:00AM 3 Healthcare Stocks That Might Skyrocket When COVID Is OverThe Motley Fool
Sep-04-21 07:55AM Why Vertex Is Expanding a Gene-Editing Partnership -- and It's not With CRISPR TherapeuticsThe Motley Fool
Sep-03-21 12:55PM Intellia's Bold Bet Pays Off, Justifying Its ValuationSeeking Alpha
Sep-02-21 10:15AM 2 of the Best Stocks to Buy Right Now with Just $500The Motley Fool
Aug-31-21 09:40AM Could CRISPR Therapeutics Stock Help You Retire a Millionaire?The Motley Fool
Aug-30-21 03:12AM CRISPR Therapeutics: Still A Solid Bet - Sickle Cell Disease Approval Possible Within 3 YearsSeeking Alpha
Aug-27-21 06:55AM The 3 Best Biotech Stocks to Buy Right NowThe Motley Fool
Aug-25-21 09:36AM Vertex (VRTX) Inks New Deal for CRISPR Gene-Editing RightsZacks Investment Research
07:21AM 3 Cathie Wood Stocks to Buy and Hold for DecadesThe Motley Fool
Aug-24-21 09:30AM Earnings Growth & Price Strength Make CRISPR Therapeutics AG (CRSP) a Stock to WatchZacks Investment Research
Aug-23-21 01:26AM Why Shares of Global Blood Therapeutics Are Soaring TodayThe Motley Fool
05:51AM 3 Growth Stocks to Buy That Wall Street Thinks Could Soar by 30% or MoreThe Motley Fool
Aug-18-21 06:15AM 3 Beaten-Down Biotech Stocks to Buy Right NowThe Motley Fool
Aug-17-21 10:21AM Editas (EDIT) Up More Than 70% in Past 3 Months: Here's WhyZacks Investment Research
Aug-14-21 08:00AM How Are Genomics ETFs Responding to Q2 Earnings?Zacks Investment Research
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient. The company is also developing CTX101, a donor-derived gene-edited allogeneic CAR-T therapy targeting CD19-positive malignancies. In addition, it is developing earlier stage allogeneic CAR-T programs targeting B-Cell maturation antigen and CD70; hemoglobinopathies to treat other diseases, including Hurler Syndrome and severe combined immunodeficiency disease; programs that are in preclinical development for indications, including glycogen storage disease Ia and hemophilia; and programs targeting diseases of organ systems outside the liver, such as Duchenne muscular dystrophy and cystic fibrosis. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated Vertex Pharmaceuticals (Europe) Limited to develop, manufacture, commercialize, sell, and use therapeutics. The company also has research collaboration agreements with Neon Therapeutics for developing neoantigen-based therapeutic vaccines and T cell therapies; Massachusetts General Hospital Cancer Center to develop T cell therapies for cancer; and with the ViaCyte, Inc. for designing allogeneic cell therapies derived from gene edited human stem cells for use in the treatment of diabetes type 1, diabetes type 2, and insulin dependent diabetes. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
Cap:    |  Volume (24h):